AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

The regulatory nod goes to risankizumab, a drug that North Chicago, Illinois-based AbbVie already sells under the name “Skyrizi” for approved uses in plaque psoriasis and psoriatic arthritis.

AbbVie has also submitted an application to the FDA, seeking the label expansion for Skyrizi to include the UC indication in the United States. The regulatory filing is yet to be accepted for review.

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise ...

Improved sales expectations for Skyrizi and Rinvoq and acquisitions in oncology and neuroscience add confidence AbbVie can continue growing. I now see EPS growing at 8.2% per year through 2030 ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

Humira revenues were $2.23 billion (down 37.2%), Skyrizi sales reached $3.21 billion (up 50.8%), and Rinvoq revenues were $1.61 billion (up 45.3%). Also Read: FDA Approves AbbVie’s Parkinson ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...